Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Michael S. Khodadoust, MD PhD, Tatyana A. Feldman, MD, Dok Hyun Yoon, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Dejan Radeski, MBBS, FRACP, FRCPA, Youn H. Kim, MD, Neha Mehta-Shah, MD, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Ryan A. Wilcox, MD, Won Seog Kim, MD PhD, Steven M. Horwitz, MD, Joseph J. Buggy, PhD, Andrew Hotson, PhD, Craig M. Hill, PhD, Brian Munneke, PhD, Suresh Mahabhashyam, MD, Richard A. Miller, MD, James W. Janc, PhD, Mehrdad Mobasher, MDMPH

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137782

Published: 2020

Journal Articles

Patient Characteristics of Long-Term Responders to Mogamulizumab: Results from the MAVORIC Study

Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Adele de Masson, MD PhD, Hélène Moins-Teisserenc, Takahiro Ito, MSc, Karen Dwyer, BA, Fiona Herr, PhD, Martine Bagot, MD PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141379

Published: 2020

Journal Articles

Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma

Tanaya Shree, MDPhDBA, Michael S. Khodadoust, MD PhD, Debra K. Czerwinski, BA, Matthew J. Frank, MD PhD, Sara Beygi, MD, Steven R. Long, MD, Brock Martin, MD, Ronald Levy, MD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-141377

Published: 2020

Journal Articles

Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Joseph G Schroers-Martin, MD, Joanne Soo, MD, Gabriel Brisou, MD, Florian Scherer, MD, David M. Kurtz, MDPhD, Brian Sworder, MD PhD, Michael S. Khodadoust, MD PhD, Michael C. Jin, BS, Agnès Bru, Chih Long Liu, PhD, Henning Stehr, PhD, Paolo Vineis, PhD, Yasodha Natkunam, MD PhD, Bertrand Nadel, PhD, Maximilian Diehn, MD PhD, Sandrine Roulland, PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-142761

Published: 2020

Journal Articles

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

Navika D Shukla, Alexander F. M. Craig, MPhil, Brian Sworder, MD PhD, David M. Kurtz, MDPhD, Charles Macaulay, MSc, BA, Andrea Garofalo, BS, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, George Duran, BA, Youn H. Kim, MD, James Zehnder, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD, Maximilian Diehn, MD PhD, Michael S. Khodadoust, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-141655

Published: 2020

Journal Articles

A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma

Tanaya Shree, MD PhD, Michael S. Khodadoust, MD PhD, Debra K. Czerwinski, BA, Matthew J. Frank, MD PhD, Wan X. Hong, MD, Rachel Greenstein, Steven R. Long, MD, Brock Martin, MD, Ronald Levy, MD

Blood (2019) 134 (Supplement_1): 2825.

https://doi.org/10.1182/blood-2019-129661

Published: 2019

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 550.

https://doi.org/10.1182/blood-2019-129015

Published: 2019

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation

Karan R. Kathuria, Binbin Chen, PhD, Michael S. Khodadoust, MD PhD, Niclas Olsson, PhD, Mark M Davis, PhD, Joshua E Elias, PhD, Ronald Levy, MD, Russ B. Altman, MD PhD, Arash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 84.

https://doi.org/10.1182/blood-2019-129334

Published: 2019

Journal Articles

Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment

Lisa E Wagar, PhD, Brian Sworder, MD PhD, Michael S. Khodadoust, MD PhD, Mark M Davis, PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 2799.

https://doi.org/10.1182/blood-2019-131192

Published: 2019

Journal Articles

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Christian M. Schuerch, MD PhD, Darci J. Phillips, MD PhD, Salil S. Bhate, MMath, Graham L. Barlow, BA, Steven P Fling, PhD, Nirasha Ramchurren, Robert Pierce, MD, Martin A Cheever, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Garry P. Nolan, PhD

Blood (2019) 134 (Supplement_1): 1521.

https://doi.org/10.1182/blood-2019-125315

Published: 2019

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

Blood (2018) 132 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2018-99-117244

Published: 2018

Journal Articles

Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma

Debra K. Czerwinski, BA, Matthew J. Frank, MD PhD, Tanaya Shree, MD PhD BA, Michael S Khodadoust, MD PhD, Steven R. Long, MD, Ronald Levy, MD

Blood (2018) 132 (Supplement 1): 1612.

https://doi.org/10.1182/blood-2018-99-119931

Published: 2018

NARROW

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Patient Characteristics of Long-Term Responders to Mogamulizumab: Results from the MAVORIC Study

Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma

Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation

Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only